Liang-Chuan Wang

Liang-Chuan Wang is a scientific leader currently serving as a Director at Incyte, a biopharmaceutical company based in Wilmington, Delaware.1 Here are some key details about his background and experience:

Professional Experience

• Current Role: Director at Incyte (since February 2023)1
• Previous Roles at Incyte:
  • Associate Director (February 2019 - January 2023)
  • Principal Investigator (July 2016 - January 2019)
  • Senior Research Investigator (October 2014 - July 2016)

Expertise and Contributions

Liang-Chuan Wang is an expert in preclinical development, focusing on various therapeutic modalities in tumor immunology.1 His areas of expertise include:

• CAR T cells
• Monoclonal and bispecific antibodies
• Small molecule immune checkpoint inhibitors
• Oncolytic virotherapy
• STING agonists

He has a proven track record in developing and implementing strategies to guide working groups and functions in delivering projects. Wang is actively involved in new target identification and the development of new platforms.1

Recent Developments

Dr. Wang has led the development of two notable molecules that have reached clinical development:

1. Oral PD-L1 small molecule inhibitors
2. PD1xTGFbR2 bispecific antibody

Both of these are first-in-human (FIH) molecules currently in clinical trials.1

Educational Background

• Ph.D. in Cancer Pharmacology from the University of Auckland (2002-2007)
• Bachelor of Technology (BTech) in Biomedical Sciences from the University of Auckland (1998-2001)1

Additional Information

Before joining Incyte, Dr. Wang held positions at the University of Pennsylvania, including:

• Research Assistant Professor (October 2013 - September 2014)
• Postdoctoral researcher (October 2008 - September 2013)1

Liang-Chuan Wang is multilingual, with proficiency in English, Japanese, and native fluency in Mandarin.1